Physician profile
Robert W Powers
NPI 1881699072
$3,254.56
in general payments reported to CMS, 2019-2025
34 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $233 · 2021: $538 · 2022: $561 · 2023: $475 · 2024: $308 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $510.76 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $483.44 | 2023-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $473.03 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $283.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $201.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $114.79 | 2019-2023 | Austedo Xr, Austedo |
| Collegium Pharmaceutical, INC. | $113.60 | 2021 | |
| Lilly USA, LLC | $102.17 | 2022-2025 | Kisunla, Trulicity |
| Indivior INC. | $86.81 | 2022-2023 | Perseris |
| Abbott Laboratories | $81.52 | 2021-2022 | |
| Novo Nordisk INC | $70.99 | 2020-2025 | Ozempic, Rybelsus |
| Sun Pharmaceutical Industries INC. | $66.66 | 2020-2021 | |
| Pfizer INC. | $61.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.26 | 2019-2020 | |
| Sanara Medtech INC. | $57.11 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.74 | 2020 | |
| Abbvie INC. | $48.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.46 | 2020-2021 | |
| Grifols USA, LLC | $35.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $34.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.93 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.86 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $23.82 | 2024 | Auvelity |
| Acadia Pharmaceuticals INC | $19.66 | 2021 | |
| Daiichi Sankyo INC. | $17.73 | 2022 | |
| Astellas Pharma US INC | $17.26 | 2019 | |
| Lundbeck LLC | $15.13 | 2025 | Rexulti |
| Amgen INC. | $14.97 | 2019 | |
| Circassia INC. | $14.92 | 2019 | |
| Dexcom, INC. | $14.85 | 2022 | |
| Biogen, INC. | $12.76 | 2020 | |
| Eisai INC. | $12.04 | 2021 | |
| Sumitomo Pharma America, INC. | $11.93 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.